Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Shlobin, Oksana A.
• dc.contributor.author Shen, Eric
• dc.contributor.author Wort, Stephen John
• dc.contributor.author Piccari, Lucilla
• dc.contributor.author Scandurra, John A.
• dc.contributor.author Hassoun, Paul
• dc.contributor.author Nikkho, Sylvia M.
• dc.contributor.author Nathan, Steven D.
• dc.date.accessioned 2024-11-06T07:17:07Z
• dc.date.available 2024-11-06T07:17:07Z
• dc.date.issued 2024
• dc.description.abstract Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until recently, the studies of pulmonary vasodilator therapy in PH-ILD have been largely disappointing, with some even demonstrating the potential for harm. This paper is part of a series of Consensus Statements from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative for Group 3 Pulmonary Hypertension, with prior publications covering pathogenesis, prevalence, clinical features, phenotyping, clinical trials, and impact of PH-ILD. It offers a comprehensive review of and a holistic approach to treatment of PH-ILD, including the management of underlying interstitial lung diseases, importance of treating the comorbidities, emphasis on importance of exercise and palliation of dyspnea, and review of the most up-to-date guidelines for referral for potential lung transplant work up. It also summarizes the prior, ongoing, and possibly future studies in treatment of the vascular derangement of this morbid condition.
• dc.format.mimetype application/pdf
• dc.identifier.citation Shlobin OA, Shen E, Wort SJ, Piccari L, Scandurra JA, Hassoun PM, et al. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension. Pulm Circ. 2024 Jan 10;14(1):e12310. DOI: 10.1002/pul2.12310
• dc.identifier.doi http://dx.doi.org/10.1002/pul2.12310
• dc.identifier.issn 2045-8932
• dc.identifier.uri http://hdl.handle.net/10230/68446
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Pulm Circ. 2024 Jan 10;14(1):e12310
• dc.rights © 2024 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Idiopathic pulmonary fibrosis
• dc.subject.keyword Management
• dc.subject.keyword Parenchymal lung disease
• dc.subject.keyword Pulmonary vascular disease
• dc.title Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion